| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 13 analysts have shared their insights on Nurix Therapeutics (NASDAQ:NRIX), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 5 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 2 | 0 | 0 | 0 |
| 3M Ago | 3 | 2 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.0, a high estimate of $31.00, and a low estimate of $10.00. Marking an increase of 4.17%, the current average surpasses the previous average price target of $24.00.
The standing of Nurix Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sudan Loganathan | Stephens & Co. | Announces | Overweight | $20.00 | - |
| Gregory Renza | RBC Capital | Raises | Outperform | $23.00 | $22.00 |
| Joel Beatty | Baird | Raises | Outperform | $25.00 | $24.00 |
| Gil Blum | Needham | Maintains | Buy | $31.00 | - |
| Gil Blum | Needham | Maintains | Buy | $31.00 | - |
| Gil Blum | Needham | Maintains | Buy | $31.00 | - |
| Gil Blum | Needham | Maintains | Buy | $31.00 | $31.00 |
| Gil Blum | Needham | Maintains | Buy | $31.00 | - |
| Terence Flynn | Morgan Stanley | Raises | Equal-Weight | $10.00 | $9.00 |
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $19.00 | $35.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $20.00 | $23.00 |
| Gregory Renza | RBC Capital | Lowers | Outperform | $22.00 | $24.00 |
| Gil Blum | Needham | Maintains | Buy | $31.00 | - |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nurix Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Nurix Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Nurix Therapeutics's remarkable performance in 3 months is evident. As of 29 February, 2024, the company achieved an impressive revenue growth rate of 30.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Nurix Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -250.33%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Nurix Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -22.49%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Nurix Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -12.43%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Nurix Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.17.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NRIX
